Trials / Completed
CompletedNCT05171751
Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia
Beijing Children's Hospital, Capital Medical University, National Center for Children's Health
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Beijing Children's Hospital · Academic / Other
- Sex
- All
- Age
- 1 Month – 18 Years
- Healthy volunteers
- Not accepted
Summary
To analyze and evaluate the efficacy and safety of octreotide subcutaneous injection in the treatment of diazazine-ineffective congenital hyperinsulinemia (CHI) in children.
Detailed description
Octreotide subcutaneous injection is effective and safe in the treatment of congenital hyperinsulinemia in children with inefficacy of diazazine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Octreotide Injection | Octreotide subcutaneous injection for congenital hyperinsulinemia with ineffective diazine |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2021-12-18
- Completion
- 2021-12-18
- First posted
- 2021-12-29
- Last updated
- 2021-12-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05171751. Inclusion in this directory is not an endorsement.